ISIN:US09076G1040

Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program

Retrieved on: 
Friday, May 3, 2024
Euronext Growth, Ratio, ADS, Therapy, American depositary receipt, ADR, Effective date, Notifiable disease

The effective date of the Ratio Change (the “Effective Date”) is expected to be April 23, 2024.

Key Points: 
  • The effective date of the Ratio Change (the “Effective Date”) is expected to be April 23, 2024.
  • ADS beneficial holders who hold through an ADR holder intermediary need not take any action in connection with the Ratio Change.
  • No new Shares will be issued in connection with the Ratio Change and this Ratio Change does not change the total number of Biophytis ordinary shares.
  • As a result of the Ratio Change, the trading price of the Company’s ADSs is expected to automatically increase proportionally, but the Company can give no assurance that the ADS trading price following the Ratio Change will be at least equal to the ADS trading price before the Ratio Change multiplied by the new 40:1 ratio.

Biophytis Announces Transfer of ADSs to OTC Market

Retrieved on: 
Friday, May 3, 2024
OTCQB, OTC, Security (finance), Therapy, OTC Markets Group

As a result of the Panel’s decision, Nasdaq will suspend trading in the Company’s ADSs effective with the opening of business on Friday, April 26, 2024, and file a Form 25 with the Securities and Exchange Commission (the “SEC”) to effect the formal delisting of the Company’s ADSs from The Nasdaq Capital Market once all applicable Nasdaq appeal and review periods have expired.

Key Points: 
  • As a result of the Panel’s decision, Nasdaq will suspend trading in the Company’s ADSs effective with the opening of business on Friday, April 26, 2024, and file a Form 25 with the Securities and Exchange Commission (the “SEC”) to effect the formal delisting of the Company’s ADSs from The Nasdaq Capital Market once all applicable Nasdaq appeal and review periods have expired.
  • The Company anticipates that, concurrent with the suspension of trading of its ADSs on Nasdaq, the Company’s ADSs will begin trading on the OTC Markets’ OTC Pink Current Information tier under the current symbol “BPTS” while it applies to trade on the higher-tier OTCQB market.
  • The Company expects that this transfer will meaningfully reduce its ongoing costs of being a publicly-traded company.
  • The Company’s ordinary shares remain listed on Euronext Growth Paris as the primary trading market and the Company intends to continue its public disclosures in compliance with applicable French financial market regulations.

Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity

Retrieved on: 
Friday, May 3, 2024
FDA, Upjohn, Cytoprotection, Research, Geriatrics, Trial of the century, Doctor of Philosophy, IND, Hepatology, Prostaglandin, Baylor University, SAB, Endocrinology, Baylor College of Medicine, Ageing, Diabetes, Euronext Growth, Gastroenterology, Wellcome Research Laboratories, Obesity, Therapy, Royal Free Hospital, Notifiable disease, Investigational New Drug, OBA, GLP1, Frailty, Consultant, MD, Facial muscles, Digestion, Patient, Metabolism, Sarcopenia, Internal medicine, Pharmaceutical industry

The OBA SAB will guide the company to develop BIO101 (20-hydroxyecdysone) in obesity, in combination with GLP1-RA, and will actively work towards the finalization of the OBA Phase 2 clinical study design.

Key Points: 
  • The OBA SAB will guide the company to develop BIO101 (20-hydroxyecdysone) in obesity, in combination with GLP1-RA, and will actively work towards the finalization of the OBA Phase 2 clinical study design.
  • Biophytis plans to file for an Investigational New Drug (IND) application to start the OBA Phase 2 clinical study in the USA with FDA in the coming weeks.
  • Stanislas Veillet, CEO de Biophytis states: “We are pleased to announce the appointment of Professor Dennis Villareal and Professor Francisco Guarner to the Scientific Advisory Board of the OBA Phase 2 study.
  • We are preparing with the SAB to file for an IND to start the OBA phase 2 clinical study in the coming weeks.”
    The first two members of Biophytis’ new Scientific Advisory Board for the OBA clinical study are:
    at Baylor College of Medicine, Houston, Texas, United States.

Biophytis announces its 2023 financial results and provides an update on its business activities

Retrieved on: 
Wednesday, April 10, 2024
Annual, Notifiable disease, Annual report, Conference, Obesity, Euronext Growth, Goldman Sachs, Disease, MDA, Partnership, Risk, COVID-19, Patient, Duchenne muscular dystrophy, Sarcopenia, University, Respiratory failure, Clinical trial, Therapy, FDA, Pharmaceutical industry

2024: The actual start of the study will depend on the conclusion of partnership agreements and Biophytis' financial resources.

Key Points: 
  • 2024: The actual start of the study will depend on the conclusion of partnership agreements and Biophytis' financial resources.
  • Promising preclinical results for BIO101 (20-hydroxyecdysone) in obesity, suggesting beneficial metabolic effects on muscle and fat mass.
  • On this basis, Biophytis plans to start a phase 1/2 clinical trial in 2024, depending on its financial resources.
  • There is therefore significant doubt about the Company's ability to continue its business activities.

Biophytis announces its 2023 financial results and provides an update on its business activities

Retrieved on: 
Wednesday, April 10, 2024
Annual, Notifiable disease, Annual report, Conference, Obesity, Euronext Growth, Goldman Sachs, Disease, MDA, Partnership, Risk, COVID-19, Patient, Duchenne muscular dystrophy, Sarcopenia, University, Respiratory failure, Clinical trial, Therapy, FDA, Pharmaceutical industry

2024: The actual start of the study will depend on the conclusion of partnership agreements and Biophytis' financial resources.

Key Points: 
  • 2024: The actual start of the study will depend on the conclusion of partnership agreements and Biophytis' financial resources.
  • Promising preclinical results for BIO101 (20-hydroxyecdysone) in obesity, suggesting beneficial metabolic effects on muscle and fat mass.
  • On this basis, Biophytis plans to start a phase 1/2 clinical trial in 2024, depending on its financial resources.
  • There is therefore significant doubt about the Company's ability to continue its business activities.